Moss Adams Wealth Advisors LLC Sells 32 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Moss Adams Wealth Advisors LLC decreased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 531 shares of the pharmaceutical company’s stock after selling 32 shares during the period. Moss Adams Wealth Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $214,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Northwest Investment Counselors LLC bought a new position in shares of Vertex Pharmaceuticals during the 3rd quarter valued at approximately $25,000. Highline Wealth Partners LLC purchased a new position in Vertex Pharmaceuticals during the 3rd quarter valued at $27,000. Dunhill Financial LLC boosted its stake in shares of Vertex Pharmaceuticals by 70.6% during the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 24 shares during the period. Legacy Investment Solutions LLC bought a new position in Vertex Pharmaceuticals in the 3rd quarter worth about $33,000. Finally, Truvestments Capital LLC bought a new position in Vertex Pharmaceuticals in the third quarter worth approximately $35,000. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Trading Up 1.2 %

Shares of Vertex Pharmaceuticals stock opened at $422.00 on Monday. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88. The firm’s 50-day moving average price is $440.94 and its 200 day moving average price is $466.09. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $108.68 billion, a PE ratio of -212.06, a P/E/G ratio of 2.11 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The business had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. During the same quarter in the prior year, the firm earned $3.67 earnings per share. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. On average, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on VRTX. Scotiabank boosted their price objective on shares of Vertex Pharmaceuticals from $426.00 to $430.00 and gave the stock a “sector perform” rating in a research note on Monday, December 23rd. Cantor Fitzgerald restated an “overweight” rating and issued a $480.00 target price on shares of Vertex Pharmaceuticals in a research note on Tuesday, November 5th. Truist Financial lowered their price objective on Vertex Pharmaceuticals from $550.00 to $460.00 and set a “buy” rating for the company in a research report on Monday, December 23rd. BMO Capital Markets lowered their price target on Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating for the company in a report on Friday, December 20th. Finally, Bank of America lowered their target price on shares of Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating for the company in a research note on Thursday, December 19th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $490.38.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.